FDA’s latest generic exclusivity dilemma is Merck’s Cosopt
Executive Summary
FDA is soliciting comments on how to handle approval of generics for Merck's Cosopt (dorzolamide/timolol ophthalmic solution). The product's pediatric exclusivity expires Oct. 28, and both Hi Tech and Apotex have tentatively approved ANDAs. There are two complications, FDA notes in its 1request for comment: "at least one applicant became eligible for 180-day exclusivity" by virtue of a Paragraph IV certification on Oct. 11, 2005, but more than 30 months have elapsed since then, seeming to pull one part of the trigger that would force the applicant to forfeit exclusivity. Also, Merck has requested delisting of the product's other patents, which expire in 2011, a move that could pull the part of the forfeiture trigger regarding "failure to market relating to the withdrawal of patent information." Comments on the docket (FDA-2008-N-0483) are due Sept. 19
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.